Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure A9.

Figure A9

Vaccine efficacy (VE) for respiratory syncytial virus (RSV) vaccines in older adults (age ≥ 60 years) with lower respiratory tract disease (LRTD) with 3 or more signs/symptoms (I2 0.0%, 95% CI 0.0 to 84.7; tau2 0.0; Q = 0.17, p = 0.982) [48,51,52,82].